Human Platelet Lysate

Growth factor-rich supplement for the expansion of cells in vitro

Please note that due to the high demand of this product, you may experience longer than usual wait times for order fulfillment. Please contact us for expected delivery estimates.

Human Platelet Lysate

Growth factor-rich supplement for the expansion of cells in vitro

From: 168 USD
Catalog #
(Select a product)
Growth factor-rich supplement for the expansion of cells in vitro
Add to Wish List

Overview

Human platelet lysate is a growth factor-rich cell culture supplement derived from healthy donor human platelets at U.S. Food and Drug
Administration (FDA)-licensed blood centers. Multiple donor units are pooled during manufacturing to minimize lot-to-lot variability.
Addition of an anticoagulant (e.g. Heparin Solution; Catalog #07980) is required to inhibit coagulation.
Subtype
Frozen
Cell Type
Platelets
Species
Human
Cell and Tissue Source
Peripheral Blood
Donor Status
Normal

Data Figures

Properties of Human Platelet Lysate Cell Culture Supplements for Ex Vivo Cell Expansion

Figure 1. Properties of Human Platelet Lysate Cell Culture Supplements for Ex Vivo Cell Expansion

The human platelet lysate (hPL) product recommended for the expansion of cells ex vivo varies depending on the starting cell type, intended application, and experimental compliance required. (1) Fibrinogen has not been depleted, therefore addition of an anticoagulant (e.g. Heparin Solution; Catalog #07980) is required to inhibit coagulation. (2) Fibrinogen has been depleted during manufacturing. Pharmaceutical-grade heparin derived from porcine intestine is used in the manufacturing process and the concentration of heparin in final product is ≤ 2 IU/mL. (3) Fibrinogen has been depleted during manufacturing; heparin is not added during the manufacturing process and addition of anticoagulants is not required for use of this product.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
06961, 06960, 06962
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
06961, 06960, 06962
Lot #
All
Language
English

Resources and Publications

Publications (1)

Mesenchymal Stem Cells Attenuate Asthmatic Inflammation and Airway Remodeling by Modulating Macrophages/Monocytes in the IL-13-Overexpressing Mouse Model. Y. Mo et al. Immune network 2022 oct

Abstract

Mesenchymal stem cells (MSCs) are attractive alternatives to conventional anti-asthmatic drugs for severe asthma. Mechanisms underlying the anti-asthmatic effects of MSCs have not yet been elucidated. This study evaluated the anti-asthmatic effects of intravenously administered MSCs, focusing on macrophages and monocytes. Seven-week-old transgenic (Tg) mice with lung-specific overexpression of IL-13 were used to simulate chronic asthma. MSCs were intravenously administered four days before sampling. We examined changes in immune cell subpopulations, gene expression, and histological phenotypes. IL-13 Tg mice exhibited diverse features of chronic asthma, including severe type 2 inflammation, airway fibrosis, and mucus metaplasia. Intravenous administration of MSCs attenuated these asthmatic features just four days after a single treatment. MSC treatment significantly reduced SiglecF-CD11c-CD11b+ monocyte-derived macrophages (MoMs) and inhibited the polarization of MoMs into M2 macrophages, especially M2a and M2c. Furthermore, MSCs downregulated the excessive accumulation of Ly6c- monocytes in the lungs. While an intravenous adoptive transfer of Ly6c- monocytes promoted the infiltration of MoM and Th2 inflammation, that of MSC-exposed Ly6c- monocytes did not. Ex vivo Ly6c- MoMs upregulated M2-related genes, which were reduced by MSC treatment. Molecules secreted by Ly6c- MoMs from IL-13 Tg mice lungs upregulated the expression of fibrosis-related genes in fibroblasts, which were also suppressed by MSC treatment. In conclusion, intravenously administered MSCs attenuate asthma phenotypes of chronic asthma by modulating macrophages. Identifying M2 macrophage subtypes revealed that exposure to MSCs transforms the phenotype and function of macrophages. We suggest that Ly6c- monocytes could be a therapeutic target for asthma management.
Please note that due to the high demand of this product, you may experience longer than usual wait times for order fulfillment. Please contact us for expected delivery estimates.